🌍·1d agodiscovery
OKYO Pharma’s Chief Medical Officer Acquires 20,000 Shares at $1.40 Ahead of Phase 3 Trial Launch
Publisher
K
Kalkine Media
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Kalkine Media
- Region
- Global
- Scope
- discovery
- Published
- July 22, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: Kalkine Media
Scope: discovery
Related coverage
More related coverage
Kalkine Media/4h ago
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch
The Press Democrat/4h ago
Lonza, with big Vacaville biotech campus, reports strong first half
JD Supra/4h ago
Landscape Analysis of the Integration of AI into Pharmaceutical Innovation | Part 1
Benzinga/4h ago